Arcelis™ AGS-004 dendritic cell-based immunotherapy for HIV infection

Immunotherapy

Volumn 2, Issue 4, 2010, Pages 467-476

  Routy, Jean Pierre ^a   Nicolette, Charles ^b  

^a MCGILL UNIVERSITY   (Canada)

^b Argos Therapeutics Inc   (United States)

Author keywords

CD40 ligand; dendritic cell; HIV; therapeutic vaccine

Indexed keywords

AGS 004; ANTIRETROVIRUS AGENT; ARCELIS; B7 ANTIGEN; CD83 ANTIGEN; CD86 ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; INTERFERON; INTERLEUKIN 12; RNA; UNCLASSIFIED DRUG; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

BIOASSAY; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL MATURATION; CELL MIGRATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DENDRITIC CELL; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG TOLERANCE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOPHENOTYPING; IMMUNOTHERAPY; IN VITRO STUDY; INFLUENZA; INJECTION SITE REACTION; INNATE IMMUNITY; LYMPHOCYTE PROLIFERATION; PATIENT SELECTION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; RNA TRANSCRIPTION; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRUS REPLICATION; ARTICLE; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; TRANSPLANTATION;

ANTI-HIV AGENTS; DENDRITIC CELLS; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOTHERAPY;

EID: 77954973455     PISSN: 1750743X     EISSN: None     Source Type: Journal    
DOI: 10.2217/imt.10.28     Document Type: Review

References (73)

1. Worm SW, De Wit S, Weber R et al.: Diabetes mellitus, preexisting coronary heart disease, and the risk of subsequent coronary heart disease events in patients infected with human immunodeficiency virus: the data collection on adverse events of anti-HIV drugs (d:A:D study). Circulation 119(6), 805-811 (2009).
2. Mocroft A, Kirk O, Gatell J et al.: Chronic renal failure among HIV-1-infected patients. AIDS 21(9), 1119-1127 (2007).
3. Lima VD, Harrigan R, Bangsberg DR et al.: The combined effect of modern highly active antiretroviral therapy regimens and adherence on mortality over time. J. Acquir. Immune Defic. Syndr. 50(5), 529-536 (2009).
4. Steigbigel RT, Cooper DA, Kumar PN et al.: Raltegravir with optimized background therapy for resistant HIV-1 infection. N. Engl. J. Med. 359(4), 339-354 (2008).
5. Little SJ, Holte S, Routy JP et al.: Antiretroviral-drug resistance among patients recently infected with HIV. N. Engl. J. Med. 347(6), 385-394 (2002).
6. Sax PE, Tierney C, Collier AC et al.: Abacavir-lamivudine versus tenofovir- emtricitabine for initial HIV-1 therapy. N. Engl. J. Med. 361(23), 2230-2240 (2009).
7. Kinloch-de Loes S: Role of therapeutic vaccines in the control of HIV-1. J. Antimicrob. Chemother. 53(4), 562-566 (2004).
8. Johnston MI, Fauci AS: An HIV vaccine - challenges and prospects. N. Engl. J. Med. 359(9), 888-890 (2008).
9. Sodora DL, Allan JS, Apetrei C et al.: Toward an AIDS vaccine: lessons from natural simian immunodeficiency virus infections of African nonhuman primate hosts. Nat. Med. 15(8), 861-865 (2009).
10. Cohen OJ, Kinter A, Fauci AS: Host factors in the pathogenesis of HIV disease. Immunol. Rev. 159, 31-48 (1997).
11. + T cell efficacy in vaccination and disease. Nat. Med. 14(6), 623-628 (2008).
12. Douek DC, Roederer M, Koup RA: Emerging concepts in the immunopathogenesis of AIDS. Annu. Rev. Med. 60, 471-484 (2009).
13. + T cells. J. Virol. 83(15), 7641-7648 (2009).
14. Ndongala Ml, Peretz Y, Boulet S et al.: HIV GAG p24 specific responses secreting IFN-γ and/or IL-2 in treatment-naive individuals in acute infection early disease (AIED) are associated with low viral load. Clin. Immunol. 131(2), 277-287 (2009).
15. Saez-Cirion A, Lacabaratz C, Lambotte O et al.: HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype. Proc. Natl Acad. Sci. USA 104(16), 6776-6781 (2007).
16. Pereyra F, Addo MM, Kaufmann DE et al.: Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy. J. Infect. Dis. 197(4), 563-571 (2008).
17. + T cell subsets expressing CD8aaand IL-7Rain viremic, aviremic and slow progressor HIV-1-infected subjects. Clin. Immunol. 124(2), 149-157 (2007).
18. Koup RA, Safrit JT, Cao Y et al.: Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J. Virol. 68(7), 4650-4655 (1994).
19. + T cell depletion in simian immunodeficiency virus-infected macaques. J. Exp. Med. 189(6), 991-998 (1999).
20. Allen TM, Oconnor DH, Jing P et al.: Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia. Nature 407(6802), 386-390 (2000).
21. + T-cell responses represents a major driving force of human immunodeficiency virus type 1 (HIV-1) sequence diversity and reveals constraints on HIV-1 evolution. J. Virol. 79(21), 13239-13249 (2005).
22. + T cells leads to reversible immune dysfunction. Nat. Med. 12(10), 1198-1202 (2006).
23. + T cell activation during HIV infection. Nat. Med. 16(4), 452-459 (2010).
24. Brenchley JM, Price DA, Schacker TW et al.: Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat. Med. 12(12), 1365-1371 (2006).
25. Jiang W, Lederman MM, Hunt P et al.: Plasma levels of bacterial DNA correlate with immune activation and the magnitude of immune restoration in persons with antiretroviral-treated HIV infection. J. Infect. Dis. 199(8), 1177-1185 (2009).
26. Naeger DM, Martin JN, Sinclair E et al.: Cytomegalovirus-specific T cells persist at very high levels during long-term antiretroviral treatment of HIV disease. PLoS One 5(1), E8886 (2010).
27. Deeks SG: Immune dysfunction, inflammation, and accelerated aging in patients on antiretroviral therapy. Top. HIV Med. 17(4), 118-123 (2009).
28. +CD25- T cells into islet-protective Foxp3+ regulatory T cells. Proc. Natl Acad. Sci. USA 104(8), 2821-2826 (2007).
29. Dalod M, Salazar-Mather TP, Malmgaard L et al.: Interferon aband interleukin 12 responses to viral infections: pathways regulating dendritic cell cytokine expression in vivo. J. Exp. Med. 195(4), 517-528 (2002).
30. Fujii S, Liu K, Smith C, Bonito AJ, Steinman RM: The linkage of innate to adaptive immunity via maturing dendritic cells in vivo requires CD40 ligation in addition to antigen presentation and CD80/86 costimulation. J. Exp. Med. 199(12), 1607-1618 (2004).
31. Coleman CM, Wu L: HIV interactions with monocytes and dendritic cells: viral latency and reservoirs. Retrovirology 6, 51 (2009).
32. Miller CJ, Hu J: T cell-tropic simian immunodeficiency virus (SIV) and simian-human immunodeficiency viruses are readily transmitted by vaginal inoculation of rhesus macaques, and langerhans cells of the female genital tract are infected with SIV. J. Infect. Dis. 179(Suppl. 3), S413-S417 (1999).
33. Lambert AA, Gilbert C, Richard M, Beaulieu AD, Tremblay MJ: The C-type lectin surface receptor DCIR acts as a new attachment factor for HIV-1 in dendritic cells and contributes to trans- and cis-infection pathways. Blood 112(4), 1299-1307 (2008).
34. Steinman RM, Banchereau J: Taking dendritic cells into medicine. Nature 449(7161), 419-426 (2007).
35. Pulendran B, Smith JL, Caspary G et al.: Distinct dendritic cell subsets differentially regulate the class of immune response in vivo. Proc. Natl Acad. Sci. USA 96(3), 1036-1041 (1999).
36. Banchereau J, Steinman RM: Dendritic cells and the control of immunity. Nature 392(6673), 245-252 (1998).
37. Steinman RM: Dendritic cells in vivo: a key target for a new vaccine science. Immunity 29(3), 319-324 (2008).
38. + T cell tolerance through PD-1 and CTLA-4. Nat. Immunol. 6(3), 280-286 (2005).
39. Napolitani G, Rinaldi A, Bertoni F, Sallusto F, Lanzavecchia A: Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat. Immunol. 6(8), 769-776 (2005).
40. Gringhuis SI, Van Der Vlist M, Van Den Berg LM, Den Dunnen J, Litjens M, Geijtenbeek TB: HIV-1 exploits innate signaling by TLR8 and DC-sign for productive infection of dendritic cells. Nat. Immunol. 11(5), 419-426
41. Randolph GJ, Angeli V, Swartz MA: Dendritic-cell trafficking to lymph nodes through lymphatic vessels. Nat. Rev. Immunol. 5(8), 617-628 (2005).
42. Shortman K, Naik SH: Steady-state and inflammatory dendritic-cell development. Nat. Rev. Immunol. 7(1), 19-30 (2007).
43. Nobile C, Petit C, Moris A et al.: Covert human immunodeficiency virus replication in dendritic cells and in DC-SIGN-expressing cells promotes long-term transmission to lymphocytes. J. Virol. 79(9), 5386-5399 (2005).
44. Tacken PJ, De Vries IJ, Torensma R, Figdor CG: Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting. Nat. Rev. Immunol. 7(10), 790-802 (2007).
45. Muthumani K, Hwang DS, Choo AY et al.: HIV-1 VPR inhibits the maturation and activation of macrophages and dendritic cells in vitro. Int. Immunol. 17(2), 103-116 (2005).
46. + T cells. Science 257(5068), 383-387 (1992).
47. Fontaine J, Coutlee F, Tremblay C, Routy JP, Poudrier J, Roger M: HIV infection affects blood myeloid dendritic cells after successful therapy and despite nonprogressing clinical disease. J. Infect. Dis. 199(7), 1007-1018 (2009).
48. Tcherepanova I, Starr A, Lackford B et al.: The immunosuppressive properties of the HIV Vpr protein are linked to a single highly conserved residue, r90. PLoS One 4(6), E5853 (2009).
49. Hansen SG, Vieville C, Whizin N et al.: Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge. Nat. Med. 15(3), 293-299 (2009).
50. + T cell responses associated with control of viremia. Science 278(5342), 1447-1450 (1997).
51. Harari A, Petitpierre S, Vallelian F, Pantaleo G: Skewed representation of functionally distinct populations of virus-specific CD4 T cells in HIV-1-infected subjects with progressive disease: changes after antiretroviral therapy. Blood 103(3), 966-972 (2004).
52. Autran B, Carcelain G, Combadiere B, Debre P: Therapeutic vaccines for chronic infections. Science 305(5681), 205-208 (2004).
53. Banchereau J, Palucka AK, Dhodapkar M et al.: Immune and clinical responses in patients with metastatic melanoma to CD34+ progenitor-derived dendritic cell vaccine. Cancer Res. 61(17), 6451-6458 (2001).
54. ORourke MG, Johnson M, Lanagan C et al.: Durable complete clinical responses in a Phase I/II trial using an autologous melanoma cell/dendritic cell vaccine. Cancer Immunol. Immunother. 52(6), 387-395 (2003).
55. + T-cell immunity. J. Immunother. 29(5), 545-557 (2006).
56. Lu W, Wu X, Lu Y, Guo W, Andrieu JM: Therapeutic dendritic-cell vaccine for simian AIDS. Nat. Med. 9(1), 27-32 (2003).
57. Kundu SK, Engleman E, Benike C et al.: A pilot clinical trial of HIV antigen-pulsed allogeneic and autologous dendritic cell therapy in HIV-infected patients. AIDS Res. Hum. Retroviruses 14(7), 551-560 (1998).
58. Lu W, Arraes LC, Ferreira WT, Andrieu JM: Therapeutic dendritic-cell vaccine for chronic HIV-1 infection. Nat. Med. 10(12), 1359-1365 (2004).
59. Garcia F, Lejeune M, Climent N et al.: Therapeutic immunization with dendritic cells loaded with heat-inactivated autologous HIV-1 in patients with chronic HIV-1 infection. J. Infect. Dis. 191(10), 1680-1685 (2005).
60. Ide F, Nakamura T, Tomizawa M et al.: Peptide-loaded dendritic-cell vaccination followed by treatment interruption for chronic HIV-1 infection: a Phase I trial. J. Med. Virol. 78(6), 711-718 (2006).
61. Connolly NC, Whiteside TL, Wilson C, Kondragunta V, Rinaldo CR, Riddler SA: Therapeutic immunization with human immunodeficiency virus type 1 (HIV-1) peptide-loaded dendritic cells is safe and induces immunogenicity in HIV-1-infected individuals. Clin. Vaccine Immunol. 15(2), 284-292 (2008).
62. Gandhi RT, ONeill D, Bosch RJ et al.: A randomized therapeutic vaccine trial of canarypox-HIV-pulsed dendritic cells vs. canarypox-HIV alone in HIV-1-infected patients on antiretroviral therapy. Vaccine 27(43), 6088-6094 (2009).
63. Marovich MA, Mascola JR, Eller MA et al.: Preparation of clinical-grade recombinant canarypox-human immunodeficiency virus vaccine-loaded human dendritic cells. J. Infect. Dis. 186(9), 1242-1252 (2002).
64. + T-cell responses during chronic untreated HIV-1 infection by immunization with subdominant cytotoxic T-lymphocyte epitopes. AIDS 23(11), 1329-1340 (2009).
65. Addo MM, Yu XG, Rosenberg ES, Walker BD, Altfeld M: Cytotoxic T-lymphocyte (CTL) responses directed against regulatory and accessory proteins in HIV-1 infection. DNA Cell Biol. 21(9), 671-678 (2002).
66. Altfeld M, Addo MM, Eldridge RL et al.: Vpr is preferentially targeted by CTL during HIV-1 infection. J. Immunol. 167(5), 2743-2752 (2001).
67. Quaranta MG, Mattioli B, Giordani L, Viora M: The immunoregulatory effects of HIV-1 Nef on dendritic cells and the pathogenesis of aids. FASEB J. 20(13), 2198-2208 (2006).
68. Tcherepanova I, Harris J, Starr A et al.: Multiplex RT-PCR amplification of HIV genes to create a completely autologous DC-based immunotherapy for the treatment of HIV infection. PLoS One 3(1), E1489 (2008).
69. Nicolette CA, Healey D, Tcherepanova I et al.: Dendritic cells for active immunotherapy: optimizing design and manufacture in order to develop commercially and clinically viable products. Vaccine 25(Suppl. 2), B47-B60 (2007).
70. Debenedette MA, Calderhead DM, Ketteringham H et al.: Priming of a novel subset of CD28+ rapidly expanding high-avidity effector memory CTL by post maturation electroporation-CD40L dendritic cells is IL-12 dependent. J. Immunol. 181(8), 5296-5305 (2008).
71. Routy JP, Boulassel MR, Yassine-Diab B et al.: Immunologic activity and safety of autologous HIV RNA-electroporated dendritic cells in HIV-1 infected patients receiving antiretroviral therapy. Clin. Immunol. 134(2), 140-147 (2010).
72. Jacobson JM, Pat Bucy R, Spritzler J et al.: Evidence that intermittent structured treatment interruption, but not immunization with ALVAC-HIV vCP1452, promotes host control of HIV replication: the results of AIDS Clinical Trials Group 5068. J. Infect. Dis. 194(5), 623-632 (2006).
73. Lebouche B, Tremblay P, Quesnel M et al.: Participants perceptions and representations after dendritic cell immunotherapy and HAART discontinuation in the CTN 239 study. Can. J. Infect. Dis. Med. Microbiol. 21(Suppl. B), 73 (2010).